Investigational Drug Information for ELX-02
✉ Email this page to a colleague
What is the development status for investigational drug ELX-02?
ELX-02 is an investigational drug.
There have been 8 clinical trials for ELX-02.
The most recent clinical trial was a Phase 1 trial, which was initiated on July 25th 2022.
The most common disease conditions in clinical trials are Genetic Diseases, Inborn, Fibrosis, and Cystic Fibrosis. The leading clinical trial sponsors are Eloxx Pharmaceuticals, Inc., SGS Life Sciences, and SGS Life Sciences, a division of SGS Belgium NV.
There are five US patents protecting this investigational drug.
Summary for ELX-02
| US Patents | 5 |
| International Patents | 0 |
| US Patent Applications | 22 |
| WIPO Patent Applications | 35 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2022-07-25) |
| Vendors | 7 |
Recent Clinical Trials for ELX-02
| Title | Sponsor | Phase |
|---|---|---|
| A Study of ELX-02 in Patients With Alport Syndrome | Eloxx Pharmaceuticals, Inc. | Phase 2 |
| A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele | Eloxx Pharmaceuticals, Inc. | Phase 2 |
| A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele | Eloxx Pharmaceuticals, Inc. | Phase 2 |
Clinical Trial Summary for ELX-02
Top disease conditions for ELX-02
Top clinical trial sponsors for ELX-02
US Patents for ELX-02
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ELX-02 | ⤷ Start Trial | L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof | Enyo Pharma SA | ⤷ Start Trial |
| ELX-02 | ⤷ Start Trial | Modulators of cystic fibrosis transmembrane conductance regulator | Vertex Pharmaceuticals San Diego LLC , Vertex Pharmaceuticals Inc | ⤷ Start Trial |
| ELX-02 | ⤷ Start Trial | Modulators of cystic fibrosis transmembrane conductance regulator | Vertex Pharmaceuticals Inc | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
